

UNITED STATES PATENT APPLICATION

OF

**NNOCHIRI N. EKWURIBE
BALASINGAM RHADAKRISHNAN
CHRISTOPHER H. PRICE
WES ANDERSON JR.
ASLAM M. ANSARI**

FOR

"BLOOD-BRAIN BARRIER THERAPEUTICS"

INTELLECTUAL PROPERTY / TECHNOLOGY LAW

P.O. BOX 14329 • RESEARCH TRIANGLE PARK, NC 27709

1. BACKGROUND OF THE INVENTION

5 1.1 FIELD OF THE INVENTION

The present invention relates to amphiphilic oligomer conjugates capable of traversing the blood-brain barrier ("BBB") and to methods of making and using such conjugates. The conjugates of the invention comprise therapeutic agents such as proteins, peptides, nucleosides, nucleotides, antiviral agents, antineoplastic agents, antibiotics, etc., and 10 prodrugs, precursors, derivatives and intermediates thereof, chemically coupled to amphiphilic oligomers.

1.2 DESCRIPTION OF THE RELATED ART

In the field of pharmaceutical and therapeutic invention and the treatment of disease states and enhancement of physiological conditions associated with the CNS, a wide 15 variety of therapeutic agents have been developed, including proteins, peptides, nucleosides, nucleotides, antiviral agents, antineoplastic agents, antibiotics, etc., and prodrugs, precursors, derivatives and intermediates thereof.

Additionally, the many known neuroactive peptides offer additional possibilities for useful 20 therapeutic agents. Such neuroactive peptides play important biochemical roles in the CNS, for example as neurotransmitters and/or neuromodulators. Delivery of this diverse array of peptides to the CNS provides many opportunities for therapeutic benefit. For example, delivery of endogenous and synthetic opioid peptides, such as the enkephalins, can be used to effect analgesia.

However, a number of obstacles currently limit the use of many compounds for use as 25 CNS therapeutic agents.

First, the brain is equipped with a barrier system. The brain barrier system has two major components: the choroid plexus and the blood-brain barrier (BBB). The choroid

SEARCHED INDEXED
SERIALIZED FILED

plexus separates cerebrospinal fluid (CSF) from blood and the BBB separates brain ISF from blood.

The BBB has about 1000 times more surface area than the choroid plexus and is the primary obstacle to delivery of therapeutic compounds to the CNS. The BBB acts as a

5 selective partition, regulating the exchange of substances, including peptides, between the CNS and the peripheral circulation. The primary structure of the BBB is the brain capillary endothelial wall. The tight junctions of brain capillary endothelial cells prevent circulating compounds from reaching the brain ISF by the paracellular route. Furthermore, recent work suggests the existence of a physiological barrier at the level of
10 the basal lamina, in addition to the barrier provided by the tight junctions. Kroll *et al.*, *Neurosurgery*, Vol. 42, No. 5, p.1083 (May 1998). Other unique characteristics of the BBB include lack of intracellular fenestrations and pinocytic vesicles and a net negative charge on the luminal surface of the endothelium. *Id.*

15 The mechanisms by which substances may traverse the BBB may generally be divided into active and passive transport mechanisms. Lipophilic molecules readily traverse the BBB by passive transport or diffusion through the endothelial plasma membranes. In contrast, hydrophilic molecules, such as peptides, typically require an active transport system to enable them to cross the BBB. Certain larger peptides, such as insulin, have receptors on the luminal surface of the brain capillaries which act as active transcytosis
20 systems.

25 Diffusion of many therapeutic compounds, such as peptides, across the BBB is also inhibited by size. For example, cyclosporin, which has a molecular weight of ~1200 Daltons (Da), is transported through the BBB at a much lower rate than its lipid solubility would predict. Such divergence between lipid solubility and BBB permeation rates is probably due to steric hinderances and is common where the molecular weight of a compound exceeds 800-1000 Da.

A further barrier to peptide delivery to the CNS is metabolic instability. In particular, before peptides injected into the blood reach the CNS, they must survive contact with enzyme degrading enzymes in the blood and in the brain capillary endothelium. BBB
30 enzymes are known to degrade most naturally occurring neuropeptides. Orally

60020P-B6262460

administered peptides face additional barriers discussed below. Metabolically stabilized peptides may exhibit increased resistance to certain enzymes; however, it has not been possible to protect peptides from the wide range of peptide-degrading enzymes present in the blood and BBB.

5 Another difficulty inherent in delivering peptides to the BBB is that successful
transcytosis is a complex process which requires binding at the luminal or blood side of
the brain capillary endothelium, movement through the endothelial cytoplasm, and
exocytosis at the abluminal or brain side of the BBB. Peptides may bind to the luminal
membrane of the brain capillary endothelium or undergo binding and endocytosis into
10 the intracellular endothelial compartment without being transported into the CNS.

In any event, many currently existing drug substances, especially peptides, are unable to overcome these structural and metabolic barriers to enter the BBB in sufficient quantities to be efficacious. There is therefore a need for pharmaceutical compositions which can (1) withstand degradative enzymes in the blood stream and in the BBB and (2) which can penetrate through the BBB in sufficient amounts and at sufficient rates to be efficacious.

Many attempts have been made in the art to deliver therapeutic compounds, such as peptides, to the CNS with varying levels of success. Such attempts can generally be grouped into two categories: invasive and pharmacological.

20 Invasive delivery strategies include, for example, mechanical procedures, such as implantation of an intraventricular catheter, followed by pharmaceutical infusion into the ventricular compartment. Aside from general considerations relating to the invasiveness of mechanical procedures, a major difficulty with mechanical approaches is the lack of peptide distribution. For example, injection of peptides into the CSF compartment 25 results in very little distribution beyond the surface of the brain. This lack of distribution is due in part to rapid exportation of peptides to the peripheral circulation.

Another invasive strategy for delivering therapeutic compounds to the CNS is by intracartoid infusion of highly concentrated osmotically active substances, such as mannitol or arabinose. Their high local concentration causes shrinkages of the brain

capillary endothelial cells, resulting in a transient opening of the tight junctions which enable molecules to traverse the BBB. Such procedures have considerable toxic effects, including inflammation, encephalitis, etc. Furthermore, such procedures are not selective: the opening of the tight junctions of the BBB permits many undesirable

5 substances to cross the BBB along with the therapeutically beneficial molecule. For a recent review of osmotic opening and other invasive means for traversing the BBB, see Kroll, Robert A. *Neurosurgery*, Vol. 42, No. 5, May 1998.

While the risks involved in these invasive procedures may be justified for life-threatening conditions, they are generally not acceptable for less dramatic illnesses. There is therefore a need for less invasive, non-mechanical and safer means for enabling therapeutic compounds to cross the BBB.

As noted above, lipophilic substances can generally diffuse freely across the BBB. Accordingly, a common pharmacological strategy for enabling peptides to traverse the BBB is to chemically modify the peptide of interest to make it lipid-soluble. Hydrophilic drug substances have been derivatized with short chain or long chain fatty acids to form prodrugs with increased lipophilicity.

Prodrugs are biologically inert molecules which require one or more metabolic steps to convert them into an active form. A difficulty with the prodrug approach to crossing the BBB is that the cleavage necessary to yield an active drug may not occur with sufficient efficiency and accuracy to produce an efficacious amount of the drug.

There is therefore a need for modified stable therapeutic compounds, such as peptides, which are capable of traversing the BBB but which retain all or part of their efficacy without requiring metabolic steps to convert them into an active form

25 A further difficulty with lipidized prodrugs is that they pass in and out of the CNS so readily that they may never reach sufficient concentration in the CNS to achieve their intended function. For example, previous attempts have been made to engineer enkephalin conjugates which can traverse the BBB. See Partridge, W.M., "Blood-Brain Barrier Transport and Peptide Delivery to the Brain," *Peptide-Based Drug Design: Controlling Transport and Metabolism*, p. 277 (1995). However, these strategies

required the subcutaneous delivery of frequent and massive doses of peptide to induce analgesia. Frequent and/or massive dosing is inconvenient to the patient and may result in serious side effects.

There is therefore a need in the art for means for enabling therapeutic agents, such as

5 peptides, to cross the BBB in a controlled manner which permits accumulation of sufficient quantities of the therapeutic in the brain to induce the desired therapeutic effect.

Another pharmacological method for delivering peptides across the BBB is to covalently couple the peptide of interest to a peptide for which a specific receptor-mediated

10 transcytosis system exists. For example, it is theoretically possible to attach β -endorphin, which is not normally transported through the BBB, to insulin to be transported across the BBB by insulin receptor-mediated transcytosis. Upon entry into the brain interstitial space, the active peptide (β -endorphin) is then released from the transport vector (insulin) to interact with its own receptor.

15 However, the difficulty with this system is designing a chimeric molecule which can become detached upon entry into the interstitial space; to the inventor's knowledge, this has not yet been achieved. Additionally, the poor stoichiometry of the neuropeptide to the carrier molecule limits the mass of the target peptide. Furthermore, receptor-mediated cellular transport systems typically have physiologically limited transport capacity. This is a rate-limiting factor which can prevent entry of pharmaceutically active amounts of peptide.

There is therefore a need in the art for means for enabling therapeutic substances, such as peptides, to cross the BBB by diffusion so as to avoid the limitations inherent in receptor-mediated transport.

25 Other pharmacological strategies include using an active fragment of a native peptide; modification of a native peptide to increase blood-brain barrier (BBB) transport activity; and delivery of a gene encoding the neuropeptide to the brain.

Oral administration is a desirable and convenient route of administration; however, orally delivered peptides must overcome a series of barriers before they can enter the blood stream. Such peptides must survive proteolysis and the acidic environment of the stomach, gastric and pancreatic enzymes, exo- and endopeptidases in the intestinal
5 brush border membrane.

There is therefore a need for orally administered peptides which can also resist proteolytic enzymes in the blood and BBB and which can traverse the BBB in sufficient quantities to provide broad distribution of drugs into the entire brain parenchyma.

10 Methionine-enkephalin and leucine-enkephalin are naturally occurring analgesic pentapeptides. These peptides and their analogs are known to act as neurotransmitters or modulators in pain transmission. Their analgesic properties are short in duration. When administered by intracerebroventricular injection, the duration of their action is also transient.

15 These properties make the enkephalins attractive compounds for use as therapeutic agents, for mediating analgesia and providing a viable alternative to morphine. However, in order to deliver enkephalins across the BBB, they must be protected against rapid degradation by aminopeptidases and enkephalinases. Furthermore, since enkephalins are hydrophilic peptides, they must be modified to provide them with increased lipophilic characteristics before they can passively diffuse across the BBB into
20 the CNS.

The attractive therapeutic properties of enkephalins have been known for some time, and many investigators have attempted to enhance the ability of enkephalins to traverse the BBB.

25 Schroder et al., *Proc. Int. Symp. Control Rel. Biact. Material*, Vol. 23, p. 611 (1996) teaches that Dalargin, a leu-enkephalin analogue can be incorporated in nanoparticles formed by polymerization of butylanoacrylate. The particles are coated with polysorbate, a penetration enhancer. Analgesic activity is obtained after intravenous administration. Unlike the present invention, however, the Schroder peptide must be chemically bound

606207-062460

to the polymeric material or to the polysorbate. The formulation is therefore a physical mixture of active drug and polymeric material.

Tsuzuki *et al.*, *Biochem. Pharm.* Vol. 41, p. R5 (1991) teaches that analogues of leu-enkephalin can be derivatized with adamantane moiety to obtain lipophilic enkephalin 5 that shows an antinociceptive effect after subcutaneus administration. Modification at the N-terminus abolishes activity while the derivative at the C-terminus through ester bond retains activity. It is postulated that the activity is obtained after cleavage of the adamantane moiety. The derivative is therefore a prodrug, a concept not consistent with aspects of the present invention in which the therapeutic conjugate retains the activity of 10 the native peptide.

Prokai-Tatra, *J. M. Chem.*, Vol. 39, p. 4777 (1996) teaches that a leucine-enkephalin analogue can be modified with chemical delivery system which is based on a 15 retrometabolic drug design. The enkephakin analogue is derivatized with a dihydropyridine moiety at the N-terminus and a lipophilic moiety at the C-terminus. After intravenous administration of the conjugate, analgesic response is observed. It is postulated that the lipophilic modification at the C-terminus enables penetration into the CNS, while the dihydropyridine moiety undergoes oxidative transformation to generate a charged moiety which restricts the peptides from effluxing into the circulatory system. Cleavage of the peptide from this moiety restores the observed analgesic activity. The 20 derivatized peptide is inactive and regains activity only after metabolic transformation. The product is therefore a pure prodrug, requiring metabolic transformation to transform it into an active form.

U.S. Patent 4,933,324 to Shashoua teaches that certain natural fatty acids can be 25 conjugated to neuroactive drugs. A highly unsaturated fatty acid of twenty-two (22) carbon chain length is particularly preferred. Administration of the conjugate shows absorption into the brain. As is the case with adamantane conjugation, this approach requires metabolic transformation of the prodrug conjugate of enkephalin to restore the activity of the enkephalin peptide.

There is therefore a compelling need in the art for pharmaceutically acceptable and effective therapeutic/diagnostic compositions capable of traversing the BBB without substantial loss or diminution of their therapeutic or diagnostic character.

2. SUMMARY OF THE INVENTION

5 The present invention broadly relates to therapeutic and/or diagnostic drug-oligomer conjugates wherein a drug molecule is covalently bonded to an oligomer to form an amphiphilic conjugate. In one aspect, the oligomer comprises at least one lipophilic moiety and at least one hydrophilic moiety, and the size and nature of the amphiphilic and lipophilic moieties is so selected as to impart an amphiphilic nature to the resulting 10 conjugate.

The present invention relates generally to amphiphilic drug-oligomer conjugates capable of traversing the BBB and to methods of making and using such conjugates.

In one aspect, the therapeutics are neuroactive drugs, proteins, peptides and especially enkephalin analogues. The conjugates are stable in the environment of the bloodstream 15 and resist degradation by the enzymes of the BBB and in the CNS. Furthermore, the conjugates readily traverse the BBB.

In one aspect, the drug-oligomer conjugates produce their intended pharmacological effect without undergoing metabolic cleavage of the oligomer.


20 In another aspect, the lipophile and hydrophile are connected by a labile, hydrolyzable bond. When the bond is hydrolyzed in the CNS, the hydrophile remains attached to the drug.

The amphiphilic oligomers are composed of lipophilic and hydrophilic moieties. The 25 lipophilic moieties are preferably natural fatty acids or alkyl chains. Preferably, the fatty-acid moiety is a straight chain molecule having (saturated or unsaturated) carbon atoms and suitably ranges from four (4) to twenty-six (26) carbon atoms. Most preferably, the fatty acid has from fourteen (14) to twenty-two (22) carbon atoms.

The hydrophilic moieties are preferably small segment of polyethylene glycol (PEG), preferably having 1-7 PEG units, and more preferably 1-5 PEG units. The length and composition of the lipophilic moieties and the hydrophilic moieties may be adjusted to obtain desired amphiphilicity.

5 In another aspect, a cholesterol or adamantane moiety is substituted for straight chain fatty acid portion of the oligomers.

Examples of preferred oligomers are as follows:



wherein n=3 to 25 and m=1 to 7;



wherein n=3 to 25 and m=1 to 6;




wherein n=3 to 25 , m=1 to 7 and X=O;




15 wherein m=0 to 5 and R=cholesterol or adamantane; or



wherein m=0 to 5;



wherein m=0 to 7;




wherein m=1 to 7 and X=N or O.


Other unsaturated fatty acid moieties which can be used according to the present invention include oleic, linoleic, and linolenic.

For example, in one aspect, the lipophile and hydrophile are connected by hydrolyzable bonds. It is preferred to provide hydrolyzable bonds between the fatty acid and hydrophilic moieties. This permits hydrolysis to occur after penetration into the CNS, thus releasing the active peptides with the hydrophilic group still attached to the peptide. As a result, the peptide acquires a more hydrophilic character and efflux to the circulatory system is thereby hindered.

10 Exemplary conjugates having non-hydrolyzable bonds are as follows:



20 ~~DHA MET-ENKEPHALIN-LYS~~



40 ~~CETYL MET-ENKEPHALIN-LYS~~


5

In another aspect, the lipophile and hydrophile are connected by hydrolizable bonds.

For example:

10

$\text{H}_2\text{N}-\text{Tyr}-\text{Gly}-\text{Gly}-\text{Phe}-\text{Met}-\text{Lys}-\text{COOH}$




15

*Sub
a6*

CHOLESTEROL-MET-ENKEPHALIN-LYS-

20

$\text{H}_2\text{N}-\text{Tyr}-\text{Gly}-\text{Gly}-\text{Phe}-\text{Met}-\text{Lys}-\text{COOH}$



25


*Sub
a7*

PALMITATE-TEG-MET-ENKEPHALIN-LYS-


30

35

40



$\text{HN}-\text{Tyr}-\text{Gly}-\text{Gly}-\text{Phe}-\text{Met}-\text{Lys}-\text{COOH}$



*Sub
a8*

DI-PALMITATE-TEG-MET-ENKEPHALIN-LYS-

In one aspect, the covalent bond between the oligomer and the drug is preferably amide (a carboxy group of the oligomer is linked to an amine group of the peptide drug), or


5 carbamate (an chloroformate group of the oligomer is linked to an amine group of the peptide drug). In general, the derivitizable amine group of the peptide is the amine of the N-terminus or a nucleophilic amino residue, usually found on the epsilon amino residue of a lysine residue.

In another aspect, an ester (a carboxy group of the peptide is covalently coupled to a 10 hydroxyl group of the oligomer or a carboxy group of the oligomer is covalently coupled to a hydroxyl group of the drug), amide (a carboxy group of the oligomer is linked to an amine group of the drug) or carbamate (an chloroformate group of the oligomer is linked to an amine group of the drug) bond is provided for non-peptide drugs.

15 For the enkephalin analogues, the preferred peptides are leu-enkephalin lysine and met-enkephalin lysine. The amino side chain of the lysine is preferably utilized in bonding.

The amphiphilic drug-oligomer conjugate may comprise multiple oligomers of differing compositions.

20 In another aspect, the amphiphilic drug-oligomer conjugates moieties are configured as follows:



Wherein R=alkyl₁₋₂₆, cholesterol or amantane.

In another aspect of the amphiphilic oligomer moieties are sugar moieties coupled to natural fatty acids and segments of polyethylene glycol. The PEG moiety serves to

increase the amphiphilicity of the fatty sugar. Examples of arrangements including sugar moieties are provided in Figures 1A-1C.

In another aspect, PEG is used as a spacer group in the amphiphilic conjugate and the length and number of the PEG moieties can be varied to refine the amphiphilicity of the

5 conjugate. Increasing the number of PEGs increases the hydrophilicity of the conjugate.

In another aspect of the invention, a proline or alanine is added to the N-terminus of the peptide. In a preferred aspect, a proline or alanine is added to the N-terminus of an enkephalin peptide and the oligomer moiety is coupled to the N-terminus of the proline

10 or alanine residue.

After absorption into the central nervous system, the esters of the fatty sugar are hydrolyzed leaving a hydrophilic moiety. Efflux is hindered and the brain aminopeptidases cleave the proline or alanine portion leaving the peptide to regain full activity.

15 The invention also provides a pharmaceutical composition comprising an amphiphilic drug-oligomer conjugate and a pharmaceutically acceptable carrier.

In another aspect, a pharmaceutical composition is provided comprising (1) a mixture of an enkephalin conjugate according to the present invention wherein the enkephalin peptide has proline or alanine added to its N-terminus and an enkephalin conjugate

20 according to the present invention which does not have a proline or alanine added to the N-terminus, and (2) a pharmaceutical carrier. This aspect provides a faster acting sustained dose of enkephalin.

The invention also provides methods of administering a conjugate of the invention.

The invention further provides assays, both in vitro and in vivo, for testing the efficacy of

25 the conjugates of the invention.

Other objects and further scope of applicability of the present invention will become apparent from the detailed description given hereafter. It should be understood that the

E0520P-38252460

detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications will become apparent to those skilled in the art from the detailed description.

5 2.1 DEFINITIONS

As used herein, the term "lipophilic" means the ability to dissolve in lipids and/or the ability to penetrate, interact with and/or traverse biological membranes.

As used herein, the term, "lipophilic moiety" or "lipophile" means a moiety which is lipophilic and/or which, when attached to another chemical entity, increases the

10 lipophilicity of such chemical entity, e.g., fatty acid, cholesterol.

As used herein, the term "hydrophilic" means the ability to dissolve in water.

As used herein, the term "hydrophilic moiety" or "hydrophile" refers to a moiety which is hydrophilic and/or which when attached to another chemical entity, increases the hydrophilicity of such chemical entity, e.g., sugars, PEG.

15 As used herein, the term "amphiphilic" means the ability to dissolve in both water and lipids.

As used herein, the term "amphiphilic moiety" means a moiety which is amphiphilic and/or which when attached to a peptide or non-peptide drug increases the amphiphilicity of the resulting conjugate, e.g., PEG-fatty acid oligomer, sugar-fatty acid 20 oligomer.

As used herewith, the term "neuroactive drug" is used broadly to encompass any peptide or other drug having an activity within the CNS, e.g., enkephalin, enkephalin analogues.

As used herein the term "peptide" is intended to be broadly construed as inclusive of polypeptides per se having molecular weights of up to about 10,000, as well as proteins

25 having molecular weights of greater than about 10,000.

As used herein, the term "covalently coupled" means that the specified moieties are either directly covalently bonded to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties.

- 5 As used herein, the term "drug" means a substance intended for use in the diagnosis, characterization, cure, mitigation, treatment, prevention or allaying the onset of a disease, disease state, or other physiological condition or to enhance normal physiological functioning in humans and/or in non-human animals.

656201262624460

3. BRIEF DESCRIPTION OF THE FIGURES

3.1 FIGURES 1A-1C: Formulae 8-10; amphiphilic oligomers of the present invention where in the lipophile is a sugar. In 1b and 1c, PEG is used as a spacer group. In 1A-1C a proline residue is added at the N-terminus of the enkephalin peptide.

3.2 ~~FIGURE 2: Compares the stability of the cetyl-PEG2-enkephalin-lys conjugate (non-hydrolyzable) to unconjugated enkephalin in rat brain homogenate.~~

3.3 ~~FIGURE 3: Compares the stability of the cetyl-PEG3-enkephalin conjugate (non-hydrolyzable) to unconjugated enkephalin in rat brain homogenate.~~

3.4 ~~FIGURE 4: Compares palmitate-PEG3-Enk conjugate (hydrolyzable) to unconjugated enkephalin in rat brain homogenate.~~

3.5 FIGURE 5a-5d: HPLC data showing extraction of conjugate from homogenized rat brain.

3.6 ~~FIGURE 6: Graph demonstrating competitive binding between cetyl-PEG₂-enkephalin conjugate and naloxone, an Opioid μ receptor agonist.~~

3.7 ~~FIGURE 7: Graphic comparison of analgesic effect of cetyl-PEG₂-enkephalin with clonidine (a morphine substitute).~~

3.8 FIGURE 8: Table showing results of receptor binding assays for various conjugates according to the present invention.

3.9 FIGURE 9: Exemplary synthetic scheme for an oligomer according to the present invention.

3.10 FIGURE 10: Exemplary synthetic scheme showing attachment of an oligomer to an enkephalin peptide according to the present invention.

4. DETAILED DESCRIPTION OF THE INVENTION

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

The present invention relates generally to amphiphilic drug-oligomer conjugates capable of traversing the BBB and to methods of making and using such conjugates.

5 The drugs are preferably neuro-active drugs, proteins, peptides and especially enkephalin analogues. The conjugates are stable in the environment of the bloodstream and resist degradation by the BBB. The conjugates readily traverse the BBB.

In one aspect, the conjugates produce their intended pharmacological effect without requiring metabolic cleavage of the oligomer. When cleavage of the oligomer occurs,

10 the drug retains activity.


~~15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 100100 100105 100110 100115 100120 100125 100130 100135 100140 100145 100150 100155 100160 100165 100170 100175 100180 100185 100190 100195 100200 100205 100210 100215 100220 100225 100230 100235 100240 100245 100250 100255 100260 100265 100270 100275 100280 100285 100290 100295 100300 100305 100310 100315 100320 100325 100330 100335 100340 100345 100350 100355 100360 100365 100370 100375 100380 100385 100390 100395 100400 100405 100410 100415 100420 100425 100430 100435 100440 100445 100450 100455 100460 100465 100470 100475 100480 100485 100490 100495 100500 100505 100510 100515 100520 100525 100530 100535 100540 100545 100550 100555 100560 100565 100570 100575 100580 100585 100590 100595 100600 100605 100610 100615 100620 100625 100630 100635 100640 100645 100650 100655 100660 100665 100670 100675 100680 100685 100690 100695 100700 100705 100710 100715 100720 100725 100730 100735 100740 100745 100750 100755 100760 100765 100770 100775 100780 100785 100790 100795 100800 100805 100810 100815 100820 100825 100830 100835 100840 100845 100850 100855 100860 100865 100870 100875 100880 100885 100890 100~~



wherein n=3 to 25 and m=1 to 6;




wherein n=3 to 25, and m=1 to 7;



wherein m=0 to 5 and R=cholesterol or adamantane; or



wherein m=0 to 5;



10 wherein m=1 to 7;



wherein m=1 to 7.

Other unsaturated fatty acid moieties which can be used according to the present invention include oleic, linoleic and linolenic.

15 In certain instances, it is preferred to provide hydrolyzable bonds between the polyethylene glycol and the fatty acid moieties. This permits hydrolysis to occur after penetration into the central nervous system, thus releasing the active peptides with the polyethylene glycol group still attached to the peptide. The peptides acquire a more hydrophilic character and efflux to circulatory system is thereby hindered.

31b A17

The covalent bond between the oligomer and the drug is preferably amide (a carboxy group of the oligomer is linked to an amine group of the peptide), or carbamate (a chloroformate group of the oligomer is linked to an amine group of the peptide).

31b A17

5 For non-peptide drug, the bond is preferably ester (a carboxy group of the peptide is covalently coupled to a hydroxyl group of the oligomer or a carboxy group of the oligomer is covalently coupled to a hydroxyl group of the drug), amide (a carboxy group of the oligomer is linked to an amine group of the drug) or carbamate (a chloroformate group of the oligomer is linked to an amine group of the drug). For the enkephalin analogues, the preferred peptides are leu-enkephalin lysine and met-enkephalin lysine.

10 The amino residue of the lysine is preferably utilized in bonding.


Other preferred amphiphilic moieties are sugar moieties, coupled to natural fatty acids and segments of polyethylene glycol. The PEG moiety serves to increase the amphiphilicity of the fatty sugar.

15 The length and number of the PEG moieties can be varied to refine the amphiphilicity of the conjugate. Increasing the number of PEGs increases the hydrophilicity of the resulting oligomer.

20 In certain instances, it is preferred to modify the N-terminus of an enkephalin with proline or alanine before attaching the oligomer. After absorption into the central nervous system, the esters of the fatty sugar are hydrolyzed leaving hydrophilic moiety. Easy efflux is hindered and the brain aminopeptidases cleave the proline or alanine portion leaving the peptide to regain full activity.



Where the hydrophilic moiety is a sugar, it is preferred that the sugar is a monosaccharide. The sugar may be an amino sugar or a non-amino sugar.

25 In another aspect, the oligomer is attached to the C-terminus of the peptide drug. For example:



Wherein R=alkyl₁₋₂₆, cholesterol or amantane.

In another aspect, the oligomer is attached at the N-terminus of the peptide drug. For example:



It will be appreciated by one of skill in the art that the oligomers may be attached at the carboxy terminus or at a constituent of an amino acid side chain, such as at the amino group of lysine.

10 The present invention broadly relates to therapeutic and/or diagnostic conjugates wherein the therapeutic and/or diagnostic molecule is covalently bonded to an oligomer to form an amphiphilic conjugate. In one aspect, the oligomer comprises at least one lipophilic moiety and at least one hydrophilic moiety, and the size and nature of the two moieties is so selected as to impart an amphiphilic nature to the resulting conjugate.

15 Exemplary oligomers according to the present invention are as follows:




where m=1 to 7;




where m=1 to 7;

20 $\text{CH}_3(\text{CH}_2\text{CH}=\text{CH})_6(\text{CH}_2)_2\text{CONHCH}_2\text{CH}_2(\text{OC}_2\text{H}_4)_m\text{OH},$

where m=1 to 6;




where $m=1$ to 6;



where $m=1$ to 6;




where $m=1$ to 7;



where $m=1$ to 7;



10 where $m=1$ to 6;




where $m=1$ to 6;




where $m=1$ to 6;



where $m=1$ to 6;




where $m=1$ to 7;



where m=1 to 6;



where m=1 to 6;



where m=1 to 6;




where m=1 to 7;




10 where m=1 to 7;



where m=1 to 6;



where m=1 to 6;



where m=1 to 6.

4.1 THERAPEUTIC COMPOUNDS

The invention thus comprehends various compositions for therapeutic (in vivo) application, wherein the peptide component of the conjugated peptide complex is a physiologically active, or bioactive, peptide. In such peptide-containing compositions, the conjugation of the peptide component to the oligomer may be by direct covalent bonding or indirect (through appropriate spacer groups) bonding, and the hydrophilic and lipophilic moieties may also be structurally arranged in the oligomer in any suitable manner involving direct or indirect covalent bonding, relative to one another. A wide variety of peptide species may be accommodated in the broad practice of the present invention, as necessary or desirable in a given end use therapeutic application.

10 While the description is primarily and illustratively directed to the use of enkephalin as a peptide component in various compositions and formulations of the invention, it will be appreciated that the utility of the invention is not thus limited, but rather extends to any peptide species which capable of conjugation to the oligomers herein described, or which are capable of being modified, as for example by the incorporation of a proline residue, so as to enable the peptide to be conjugated to the oligomers described herein.

Accordingly, appropriate peptides include, but or not limited to: adrenocorticotrophic hormone, adenosine deaminase ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminease, asparaginase, caerulein, calcitonin, chymotrypsin, cholecystokinin, clotting factors, dynorphins, endorphins, endorphins, 20 enkephalins, enkephalins, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, oxytocin, papain, parathyroid hormone, peptides prolactin, soluble CD-4, somatomedin, somatostatin, somatostatin, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen 25 activator, trypsin, vasopressin, and analogues of such peptides, as well as other suitable enzymes, hormones, proteins, polypeptides, enzyme-protein conjugates, antibody-hapten conjugates, viral epitopes, etc.

30 In other aspect, the therapeutic peptide of the amphiphilic drug-oligomer conjugates are as described in United States Patent 5,641,861, which is incorporated herein by reference, so long as any of such peptides contains a lysine residue. Exemplary peptides described therein include: Ac-Phe-Arg-Trp-Trp-Tyr-Lys-NH₂; Ac-Arg-Trp-Ile-

Gly-Trp-Lys—NH₂; Trp-Pro-Lys-His-Xaa—NH₂, where Xaa can be any one of the twenty naturally occurring amino acids, or Trp-Trp-Pro-Xaa—NH₂, where Xaa is Lys or Arg; Tyr-Pro-Phe-Gly-Phe-Xaa—NH₂, wherein Xaa can be any one of the twenty naturally occurring amino acids; (D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Gly_n-Xaa—NH₂, wherein Xaa is Gly or the D-form of a naturally-occurring amino acid and n is 0 or 1, peptides of this formula can be hexapeptides when Gly is absent (n is 0) and heptapeptides when Gly is present (n is 1); (D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa—NH₂, wherein Xaa is Gly or the D-form of a naturally-occurring amino acid; Tyr-A1-B2-C3—NH₂, wherein A1 is (D)Nve or (D)Nle, B2 is Gly, Phe, or Trp, and C3 is Trp or Nap; Pm and red {Me_xH_yN-Tyr-(NMe)_z-Tyr-Xaa_z—NH₂}, wherein x and y independently are 0, 1, or 2 and z is 0 or 1, and wherein Xaa is Phe D-Phe, or NHBzl.

In other aspect, the therapeutic peptide of the amphiphilic drug-oligomer conjugates are as described in United States Patent 5,602,099, which is incorporated herein by reference, with the proviso that the conjugation can occur only where there is a free carboxyl or free N-terminal. Exemplary peptides include: H-Tyr-Tic-Phe-Phe-OH; H-Tyr-carboxyl or free N-terminal. Exemplary peptides include: H-Tyr-Tic-Phe-Phe-OH; H-Tic-Phe-Phe-NH₂; Tyr(N_α Me)-Tic-Phe-Phe-OH; Tyr(N_α Cpm)-Tic-Phe-Phe-OH; Tyr(N_α Hex)-Tic-Phe-Phe-OH; Tyr(N_α Et₂)-Tic-Phe-Phe-OH; H-Dmt-Tic-Phe-Phe-OH; H-Dmt-Tic-Phe-Phe-NH₂; H-Tyr(3-F)-Tic-Phe-Phe-OH; H-Tyr(3-Cl)-Tic-Phe-Phe-OH; H-Tyr(3-Br)-Tic-Phe-Phe-OH; H-Dmt-Tic Ψ [CH₂—NH]Phe-Phe-OH; H-Dmt-Tic Ψ [CH₂—NH]Phe-Phe-NH₂; H-Tyr-Tic Ψ [CH₂—NCH₃]Phe-Phe-OH; H-Tyr-Tic- Ψ [CH₂—NH]Hfe-Phe-OH; Tyr(NMe)-Tic Ψ [CN₂—NH]Hfe-Phe-OH; H-Tyr-Tic-Phg-Phe-OH; H-Tyr-Tic-Phe-OH; H-Tyr-Tic-Atc-Phe-OH; H-Tyr-Tic-Phe-Phe(pNO₂)-OH; H-Tyr-Tic-Trp-Phe(pNO₂)-OH; H-Tyr-Tic-Phe-Trp-NH₂; H-Tyr-Tic-Phe-Rhe-Val-Val-Gly-NH₂; H-Tyr-Tic-Phe-Phe-Tyr-Pro-Ser-NH₂; H-Tyr-Tic-Trp-Phe-Tyr-Pro-Ser-NH₂; H-Tyr-Tic-Trp-Phe (pNO₂) -Tyr-Pro-Ser-NH₂ and H-Tyr-Tic-Phe-Phe-Leu-Nle-Asp-NH₂.

Abbreviations in the aforementioned peptides of U.S. Patent 5,602,099 may be interpreted as follows: Aib=α -aminoisobutyric acid; Atc=2-aminotetralin-2-carboxylic acid; Boc=tert-butoxycarbonyl; Cpm=cyclopropylmethyl; DCC=dicyclohexyl-

carbodiimide; DIEA=diisopropylethylamine; Dmt=2,6-dimethyltyrosine; Et=ethyl; Hex=hexyl; Hfe=homophenylalanine; HOBt=1-hydroxybenzotriazole; MVD=mouse vas deferens; 1-Nal=3-(1'-naphthyl)alanine; 2-Nal=3-(2'-naphthyl)alanine; Phe(pNO₂)=4-nitrophenylalanine; Phg=phenylglycine; Tic=1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; TIP=H-Tyr-Tic-Phe-OH; TIP-NH₂=H-Tyr-Tic-Phe-NH₂; TIP(Ψ)=H-Tyr-TicΨ [CH₂-NH]Phe-OH; TIPP=H-Tyr-Tic-Phe-Phe-OH; TIPP-NH₂=H-Tyr-Tic-Phe-Phe-NH₂; TIPP(Ψ)=H-Tyr-TicΨ [CH₂-NH]Phe-Phe-OH; Tyr(3-Br)=3-bromotyrosine; Tyr(3-Cl)=3-chlorotyrosine; Tyr(3-F)=3-fluorotyrosine; and Tyr(Nα Me)=Nα -methyltyrosine.

In another aspect, the peptides are as described in U.S. Patent 5,545,719, which is
10 incorporated herein by reference.

Other exemplary peptides include, for example, ACTH-related peptides for inducing neural regeneration, cyclosporin for treating infection, enkephalin analogs for treating pain and drug addiction, MIF-1 for treating depression, neurotensin for relieving pain, and peptide T for treating AIDS-associated dementia. Adrenocorticotrophic hormone
15 (ACTH) and its analogue peptides are also known to restore the avoidance learning caused by removal of the pituitary gland and can also be used to treat passive avoidance conditions.

Particularly preferred peptides are the endogenous and synthetic Opioid peptides such as the enkephalins. A particularly preferred Opioid is [Met⁵]Enkephalin (Tyr-Gly-Gly-Phe-Met).

Peptides according to the present invention may be synthesized according to any method of synthesis known in the art. Such methods include, but are not limited to chemical synthesis techniques and recombinant DNA expression techniques.

The therapeutic compounds of the present invention can be modified in order to facilitate
25 coupling to the amphiphilic oligomer. A functional group may be added to the C-terminus or the N-terminus of the peptide or to a side chain of the peptide in order to provide a point of attachment for the oligomer.

Alternatively, specific amino acids may be inserted within the amino acid chain of the peptide therapeutic, or may replace an amino acid of the therapeutic or may be added to the C-terminus or N-terminus of the peptide in order to facilitate attachment of the oligomer where such modification does not eliminate the activity of the peptide. For example, a proline or alanine residue can be added to the N-terminus of a therapeutic peptide, such as an enkephalin, such as [met⁵]enkephalin, in order to facilitate attachment of the amphiphilic oligomer.

One skilled in the art would know that one or more amino acids within the exemplified peptides could be modified or substituted, as for example, by a conservative amino acid substitution of one or more of the specific amino acids shown in the exemplified peptides. A conservative amino acid substitution change can include, for example, the substitution of one acidic amino acid for another acidic amino acid, of one hydrophobic amino acid for another hydrophobic amino acid or other conservative substitutions known in the art, including the use of non-naturally occurring amino acids, such as Nle for Leu or ornithine (Orn) or homoArginine (homoArg) for Arg.

In addition to the above types of modifications or substitutions, a mimic of one or more amino acids, otherwise known as a peptide mimetic or peptidomimetic, can also be used. As used herein, the term "mimic" means an amino acid or an amino acid analog that has the same or similar functional characteristic of an amino acid. Thus, for example, a (D)arginine analog can be a mimic of (D)arginine if the analog contains a side chain having a positive charge at physiological pH, as is characteristic of the guanidinium side chain reactive group of arginine. A peptide mimetic or peptidomimetic is an organic molecule that retains similar peptide chain pharmacophore groups as are present in the corresponding peptide.

25 The substitution of amino acids by non-naturally occurring amino acids and
peptidomimetics as described above can enhance the overall activity or properties of an
individual peptide based on the modifications to the side chain functionalities. For
example, these types of alterations can be employed along with the amphiphilic
oligomers of the present invention to further enhance the peptide's stability to enzymatic
breakdown and increase biological activity.

One skilled in the art can easily synthesize the peptides for use as therapeutics in this invention. Standard procedures for preparing synthetic peptides are well known in the art. The peptides can be synthesized using the solid phase peptide synthesis (SPPS) method of Merrifield (*J. Am. Chem. Soc.*, 85:2149 (1964), which is incorporated herein by reference) or using standard solution methods well known in the art (see, for example, Bodanzsky, M., *Principles of Peptide Synthesis* 2nd revised ed. (Springer-Verlag, 1988 and 1993), which is incorporated herein by reference). Alternatively, simultaneous multiple peptide synthesis (SMPS) techniques well known in the art can be used. Peptides prepared by the method of Merrifield can be synthesized using an automated peptide synthesizer such as the Applied Biosystems 431A-01 Peptide Synthesizer (Mountain View, Calif.) or using the manual peptide synthesis technique described by Houghten, *Proc. Natl. Acad. Sci., USA* 82:5131 (1985), which is incorporated herein by reference.

Peptides can be synthesized using amino acids or amino acid analogs, the active groups of which are protected as necessary using, for example, a t-butyldicarbonate (t-BOC) group or a fluorenylmethoxy carbonyl (FMOC) group. Amino acids and amino acid analogs can be purchased commercially (Sigma Chemical Co.; Advanced Chemtec) or synthesized using methods known in the art. Peptides synthesized using the solid phase method can be attached to resins including 4-methylbenzhydrylamine (MBHA), 4-(oxymethyl)-phenylacetamidomethyl and 4-(hydroxymethyl)phenoxyethyl-copoly(styrene-1% divinylbenzene) (Wang resin), all of which are commercially available, or to p-nitrobenzophenone oxime polymer (oxime resin), which can be synthesized as described by De Grado and Kaiser, *J. Org. Chem.* 47:3258 (1982), which is incorporated herein by reference.

A newly synthesized peptide can be purified using a method such as reverse phase high performance liquid chromatography (RP-HPLC) or other methods of separation based on the size or charge of the peptide. Furthermore, the purified peptide can be characterized using these and other well known methods such as amino acid analysis and mass spectrometry.

4.2 SYNTHESIS

A general synthesis scheme for the oligomers of the present invention is provided in FIG. 9, and a general synthesis scheme for attaching such oligomer to the therapeutic peptides of the instant invention is provided in FIG. 10.

Several methods of modifying fatty acid to achieve the desired oligomer will be discussed in further detail with structural illustrations.


In the synthesis of oligomers containing fatty acids and polyethylene glycols, where the ethylene glycol is connected to the fatty acid in a hydrolysable ester bond, it is desirable to start with the acid chloride of the fatty acid or its acid anhydride. A desired polyethylene glycol having two free hydroxyls at the termini is then treated in inert solvent with equal molar equivalent of acid chloride or acid anhydride. The glycol unit is first dissolved in inert solvent and treated with organic base before the addition of the acid chloride or acid anhydride. The product is extracted from the reaction medium and further purified using column chromatograph:



↓
Pyridine



In some instances it is desired to create oligomers that have stronger hydrolysable bond such as amide. The acid chloride or the acid anhydride of the selected fatty acid is treated with amino derivative of polyethylene glycol in a controlled reaction condition to effect only the amino residue and not the hydroxyl portion. Other conditions that ensure selectivity is by converting the fatty acid into N-hydroxysuccinimide ester and reacting with the amino residue of the polyethylene glycol.




↓
Pyridine



5



↓
THF/TEA



10 Coupling of the oligomer to the peptide drug is effected by converting the free hydroxyl moiety of the oligomer to N-hydroxysuccinimide ester (NSU). N-hydroxysuccinimide group reacts readily with the nucleophilic amino residue of the peptide.




↓



15 In the synthesis of oligomers in which the lipophilic portion of the oligomers is connected to the hydrophilic portion by ether linkage, the desired polyethylene glycol (hydrophile) is first protected. One of the two free hydroxyls at the termini is protected with a trityl group in pyridine using one mole of trityl chloride. The protected polyethylene glycol is dissolved in a suitable inert solvent and treated with sodium hydride. Bromo or tosylate derivative of the lipophilic portion is dissolved in inert solvent and added to the solution of the protected polyethylene glycol. The product is treated with a solution of para-toluenesulfonic acid in anhydrous inert solvent at room temperature. The desired


20 toluenesulfonic acid in anhydrous inert solvent at room temperature. The desired

product is extracted in inert solvent and purified by column chromatography. The structures of the transformation are depicted below:



The lipophilic portion can be alkyl, cholestryl, adamantly moieties.


In the synthesis of oligomers where the lipophilic portion of the oligomer is connected to the hydrophilic portion in ether bond and the terminal ends in carboxylic acid moiety, it is desirable to protect the carboxylic group. Polyethylene glycol having free hydroxyl group at one end and carboxylic group at the other end is selected. The carboxylic group is protected by esterification. The protected polyethylene glycol is dissolved in a suitable inert solvent and treated with sodium hydride. Bromo or tosylate derivatives of the lipophilic portion is dissolved in inert solvent and added to the solution of the protected polyethylene glycol. The product is treated with solution of sodium hydroxide to liberate free acid. The desired product is extracted in inert solvent and purified by column chromatography. The structures of the transformation are depicted below.



The lipophilic portion can be alkyl, cholestryl or adamantyl moieties.

This group of acidic oligomers can be coupled to peptide drugs by first reacting the carboxylic group with N-hydroxysuccinimide (NSU) to from easily leavable group. A solution of the activated oligomers in inert solvent is treated with the desired peptide


5 drug dissolved in a suitable solvent. Inverse addition may be selected.



Sometimes it is desirable to replace the lipophilic moiety with lipophilic sugars. The sugar moiety is first esterified with desired fatty acid chloride to obtain selective or partial acylation. The product is treated in inert solvent with diacid chloride of desired dicarboxylic acid derivative of polyethylene glycol.

15 Reaction is conducted with one molar equivalent of each reacting moiety. This reaction leaves one end of the hydrophile bearing acid chloride, which is further converted to N-hydroxysuccinimide ester. The activated ester is reacted with peptide drug in suitable inert solvent.

66207 * 86/26475-0



15 Where R=fatty acid, alkyl₁₋₂₆, cholesterol or adamantane.

4.3 THERAPEUTIC METHODS

The invention provides methods of treatment and prevention by administration to a subject of an effective amount of an amphiphilic drug-oligomer conjugate of the invention.

One embodiment of the invention provides for methods of administering a pharmaceutical composition which is comprised of a therapeutically effective amount of an amphiphilic drug-oligomer conjugate according to the present invention.

Methods of introduction include but are not limited to intradermal, intramuscular, 5 intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The conjugates may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.

10 In certain circumstances, it may be desirable to introduce the pharmaceutical compositions of the invention directly into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

15 Pulmonary or nasal administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In another embodiment, the conjugates can be delivered in a controlled release system. 20 In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 25 249:1527-1533 (1990)).

The subject is preferably an animal, including, but not limited to, animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

4.4 PHARMACEUTICAL COMPOSITIONS

Exemplary means of administration include oral, parenteral, rectal, topical, sublingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, and 5 intrauterine administration.

The present invention contemplates the use of pharmaceutical formulations for human medical use which comprise the vector structures of the present invention as therapeutic ingredients. Such pharmaceutical formulations may include pharmaceutically effective carriers, and optionally, may include other therapeutic ingredients. The carrier or 10 carriers must be pharmaceutically acceptable in the sense that they are compatible with the therapeutic ingredients and are not unduly deleterious to the recipient thereof. The therapeutic ingredient or ingredients are provided in an amount necessary to achieve the desired therapeutic effect, described below.

In another aspect, a pharmaceutical composition is provided to comprising (1) a mixture 15 of an enkephalin conjugate according to the present invention wherein the enkephalin peptide has proline or alanine added to its N-terminus and an enkephalin conjugate according to the present invention which does not have a proline or alanine added to the N-terminus, and (2) a pharmaceutical carrier.

Various delivery systems are known and can be used to administer a conjugate of the 20 invention, e.g., encapsulation microcapsules.

As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the 25 conjugate is administered.

Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean

oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.

5 Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.

The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

10 The compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.

15 Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

20 Such compositions will contain a therapeutically effective amount of the drug-oligomer conjugate, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

25 The mode of administration and dosage forms will of course affect the therapeutic amounts of the compounds which are desirable and efficacious for the given treatment application. A therapeutically effective amount is an amount necessary to prevent, delay or reduce the severity of the onset of disease, or an amount necessary to arrest or reduce the severity of an ongoing disease. It will be readily apparent to one of skill in the art that this amount will vary based on factors such as the weight and health of the

recipient, the type of cells being transformed, the mode of administration of the present compositions and the type of medical disorder being treated.

The dosage can be presented in the form of tablets, syrups, losenges, elixirs, suspensions, and/or emulsions.

5 Accessory ingredients may, without limitation, include diluents, buffers, flavoring agents, disintegrants, surfactants, thickeners, lubricants, preservatives, and/or antioxidants.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.

10 Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a

15 hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.

Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

20 The conjugates of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

6662017 0602624160

The amount of the Conjugate of the invention which will be therapeutically effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vivo* and/or *in vitro* assays may optionally be employed to help identify 5 optimal dosage ranges.

For example, suitable doses of a an enkephalin conjugate for analgesia may generally be in the range of from 1 mg/kg to 20 mg/kg, preferably 3 mg/kg to 15 mg/kg, more preferably 5 mg/kg to 7 mg/kg.

Effective doses may be extrapolated from dose-response curves derived from *in vitro* or 10 animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions 15 of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

The present invention is not to be limited in scope by the specific embodiments 20 described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

5. EXAMPLES

25 5.1 SYNTHESIS

5.1.1 TRIETHYLENE GLYCOL MONOHEXADECYL ESTER

Palmitic anhydride (5.00g; 10.104 mmol) was dissolved in dry THF (20 mL) and 3 mol excess of dry pyridine and the solution was stirred at room temperature. To the stirring solution, triethylene glycol (1.5 g; 10.104 mmol) was added slowly. After stirring for 1h, THF was removed under reduced pressure at room temperature and the reaction 5 mixture was poured into ice cold 10% sulfuric acid. The aqueous layer was extracted with ethyl acetate (30 ml x 3). Combined organic layer was sequentially washed with water, brine and dried over $MgSO_4$ and filtered. After evaporation gave pure product, single spot on TLC.

5.1.2 SUCCINIMIDYL TRIETHYLENE GLYCOL MONOHEXADECYL ESTER:

10 To a stirring solution of teg-palmitate (1 g; 2.57 mmol), dimethylaminopyridine (0.313 g; 2.57 mmol) in dry THF was added N,N'-disuccinimidyl carbonate (0.691 g) in one portion. The reaction mixture was stirred overnight at room temperature. The organic solvent was removed under reduced pressure and reaction mixture was diluted with ethyl acetate, washed with 1N hydrochloric acid (10mL x 2), water and brine. The 15 solvent was dried over $MgSO_4$, filtered and evaporated to leave white solid.

5.1.2.1 Determination of Activity

The succinimidyl reactivity was determined by conjugating it with insulin and it was found to be 67%.

5.1.3 SUCCINIMIDYL TRIETHYLENE GLYCOL MONOHEXADECYL ETHER

20 To a cold stirring solution of phosgene (10.0 mL; 20% solution in toluene) under nitrogen, a solution of triethylene glycol monohexadecyl ether (1.5 g; 4.00 mmol) in dry dichloromethane (4mL) was added. The reaction mixture was stirred at 0 °C for 2h at room temperature. Excess of phosgene was distilled off using water aspirator, passing through cold solution of dilute NaOH.

25 The reaction flask was cooled in ice bath and equimolar quantity of triethyl amine and a solution of hydroxysuccinimide, dissolved in minimum quantity of THF was added slowly. The reaction mixture was stirred at room temperature for 12h. The solvent was removed

completely at 25 °C and residue was redissolved in ethyl acetate, washed with water, brine, dried over MgSO₄ and evaporated to give pure succinimidyl derivative

5.1.3.1 DETERMINATION OF ACTIVITY

The succinimidyl reactivity was determined by conjugating it with insulin and it was found

5 to be 62.5%.

~~5.2 CONJUGATION OF COMPOUND 2 & 4 WITH MET-ENKEPHALIN~~

5.2.1 GENERAL PROCEDURE FOR CONJUGATION

5.2.1.1 SCHEME



10



5.2.1.2 GENERAL PROCEDURE

To a stirring solution of met-enkephalin (0.130 g; 0.1854 mmol) in 5mL of DMF-DCM (2:1) was added TEA (25 μ L). The reaction mixture was cooled to 10 °C and a solution

of palmityl-teg-nsu or cetyl-teg-nsu dissolved in 1mL of DCM was added in one portion.

The reaction mixture was stirred for 2h at 10 °C. The solvent was removed under reduced pressure and the residue was redissolved in dry ethyl acetate. After evaporation of the solvent 0.310g conjugated enkephalin was obtained. HPLC showed

20 mono & diconjugate in the ratio of 3.1.

5.3 SYNTHESIS OF CETYL-PEG₂; IT'S ACTIVATION & CONJUGATION WITH PROTECTED (BOC) LEUENK

To a suspension of NaH (4.00g: 0.1 mol) in dry THF (300 mL) at 10 °C was added diethylene glycol in one portion. The cooling bath was removed and reaction mixture was stirred at room temperature for 2h. At the end the reaction mixture was cooled to 10 °C and bromohexadecane (29g).095 mol was added in one portion. The cooling bath was removed and the reaction was stirred at room temperature for 4h. The solvent was removed under reduced pressure and crude was admixed with water and extracted with ethyl acetate (30 mL x 3). The combined organic extract was sequentially washed with water, brine, dried over $MgSO_4$ and evaporated to leave white solid powder, single spot on TLC and single molecular ion peak.

10 5.3.1 CETYL-PEG₂-NSU

To a cold stirring solution of phosgene (10.0mL; 20% solution in toluene) under nitrogen, a solution of cetyl-PEG₂-OH (1.3g; 4.00 mmol) in dry dichloromethane (5mL) was added. The reaction mixture was stirred at 0 °C for 1hr and 2h at room temperature. Excess of phosgene was distilled off using water aspirator, passing through cold solution of dilute 15 NaOH.

The reaction flask was cooled in ice bath and equimolar quantity of triethyl amine and a solution of hydroxy succinimide, dissolved in minimum quantity of THF was added slowly. The reaction mixture was stirred at room temperature for 12h. The solvent was removed completely at 25 °C and residue was redissolved in ethyl acetate, washed with 20 water, brine, dried over $MgSO_4$ and evaporated to give pure succinimidyl derivative.

5.3.2 DETERMINATION OF ACTIVITY

The succinimidyl reactivity was determined by conjugating it with insulin and it was found to be 83.5%.

25 5.4 CONJUGATION OF SUCCINIMIDYL CETYL-PEG2 WITH BOC-LEU... ENK... LYS-OH

Sub 034
 Boc-Leu...enk...Lys-OH (100mg; 0.125 mmol) was dissolved in 5 mL of DMF:DCM(1:1) and stirred at 10 °C under nitrogen. To this clear solution TEA (17.5 μ L) and a solution of succinimidyl cetyl-PEG₂, dissolved in 1 mL of DCM were added.

After 1.5h (TLC showed single product) the solvent was removed under reduced pressure at room temperature and reaction mixture was admixed with water and extracted with ethyl acetate (10 mL x 3). The organic extract was sequentially washed with water, brine, dried and evaporated to a solid.

Sub 035
5.4.1 PURIFICATION OF DERIVATIZED BOC-LEU...ENK...LYS-OH ON SILICA GEL COLUMN

Sub 036
 10 The derivatized blocked enkephalin was purified on silica gel column using methanol-chloroform (5% methanol-chloroform) mixture as an eluting solvent. After evaporation of desired fraction 100 mg pure compound was obtained. A product yield of 100 mg was obtained after removal of the solvent.

Sub 036
5.4.2 DEBLOCKING OF BUTYLOXYCARBONYL GROUP FROM DERIVATIZED LEU...ENK

Sub 037
 15 Derivatized Boc-Leu...enk. (100 mg: 0.0866 mmol) was treated with 0.4ml of TFA-DCM (1:1) for 30 min. at room temperature. The solvent was removed under reduced pressure. The solid was redissolved in 2ml of methanol, filtered and evaporated; 80 mg of pure product was obtained.

Sub 038
20 5.5 SYNTHESIS OF AMPHIPHILIC OLIGOMER-ENKEPHALIN CONJUGATES

Sub 038
5.5.1 A GENERAL SCHEME FOR SYNTHESIS OF NON-HYDROLYZABLE AND HYDROLYZABLE CONJUGATES

Sub 038
 25 One-hundred milligrams of enkephalin (100 mg; 0.142 mmol) was dissolved in dry dimethylformamide (5 mL) at room temperature. P-nitrophenol or N-hydroxysuccinimide activated (carbonate or ester) of amphiphilic oligomer (1.1 mole equivalent) was dissolved in 1 mL tetrahydrofuran and added to above solution and stirred at room

temperature over 1.5 hours. The extent of the reaction was monitored by a reverse phase (C-18) HPLC using isopropanol/water (0.1% trifluoracetic acid) gradient system. Reaction mixture was evaporated under reduced pressure and the contents were dissolved in an isopropanol-water mixture. This mixture was purified on a 22 mm preparative HPLC column (C-8) with a solvent gradient system made of either isopropanol/water (0.1% trifluoroacetic acid) or acetonitrile/water (0.1% trifluoroacetic acid to give pure monoconjugated and diconjugated enkephalins. The solvent was evaporated at low temperature (<20 °C) to give dry produce. The purity of the product was analyzed by reverse phase analytical HPLC, and the MW information was obtained by MALDI (TOF)-mass spectral technique.

10

5.5.2 SYNTHESIS OF CHOLESTEROL-PEG₂ HYDROLYZABLE AMPHIPHILIC OLIGOMER

PEG₂ diacid (3,6,9-trioxaundecanoic diacid, 10 g) was dissolved in dry chloroform (50 mL) and added dropwise to oxalychloride at room temperature under dry condition in the presence of catalytic amount of dimethylformamide. The reaction was stirred or 6 hours and the solvent and excess of reagent was stripped off to give an oily residue.

15

Above residue was dissolved in chloroform (50 mL) and to this was added cholesterol (1.05 mole equivalent) in chloroform (50mL) and triethylamine (1 mole equivalent) over 30 minutes at 5 °C. The reaction was stirred at 15 °C over 2 hours. To this was added N-hydroxysuccinimide (1 mole equivalent) in chloroform (50mL) and followed by triethylamine (1 equivalent) at 5 °C and allowed to stir overnight. Solvent was stripped off and the product was extracted with ethylacetate. Crude product was purified on a silica gel column with 1:10 methanol/chloroform solvent system to obtain activated amphiphilic oligomer in 80% yield.

20

25 5.6 MOLECULAR WEIGHT INFORMATION OF ENKEPHALIN CONJUGATES OBTAINED BY MALDI (TOF)-MS

| Enkephalin Conjugate | Expected M. W. | Observed M. W. |
|------------------------------|----------------|----------------|
| Cholesterol-PEG ₂ | 1274 | 1275 |

| | | |
|-----------------------------|-----------|-----------|
| DHA- PEG ₂ | 1144.4 | 1144.3 |
| Linolenic- PEG ₂ | 1093.4 | 1093.3 |
| Cetyl- PEG ₂ | Avg. 1059 | Avg. 1032 |
| Palmitate- PEG ₃ | 1116 | 1115.6 |
| Cetyl- PEG ₃ | 1101 | 1101.12 |

These results demonstrate that the reactions resulted in monoconjugates, i.e., each peptide was coupled to only one oligomer. It is significant to note that a single conjugate is sufficient to impart amphiphilic properties.

Sub a40

5.7 STABILITY OF MET ENKEPHALIN-LYS (ENKEPHALIN) AND ITS AMPHIPHILIC OLIGOMER CONJUGATES IN RAT BRAIN HOMOGENATE

Sub a41

Met enkephalin-lys and its conjugates (Cetyl-PEG₂, Cetyl-PEG₃ and Palmitate-PEG₃) were incubated in 2% rat brain homogenate. Samples were drawn over time intervals and the amount of the substance remaining was measured by a HPLC method. Following experimental procedure was used for the study.

Sub a42

Procedure: A 2% rat brain homogenate was prepared by homogenizing freshly perfused (PBS buffer) rat brain in PBS buffer (pH 7.4). Two 3-mL aliquots of the homogenate were equilibrated at 37 °C in a water bath. To one unmodified enkephalin was added and to other modified (conjugate) was added, resulting in a final concentration of 60ug/mL of peptide. At time 0, 1, 2, 3, 5, 15, 30, and 60 minutes, 200 uL of aliquot was withdrawn and quenched with 200 uL of the quenching agent (1% trifluoroacetic acid in acetonitrile/isopropanol or 1% trichloroacetic acid in water). The sample solutions were vortexed and centrifuged at 7000RPM. The supernatant was analyzed by a HPLC method using a gradient of 10 to 100% isopropanol/water (0.1% trifluoroacetic acid) on a

20 C-18 column.

Sub a43

Figure 2 shows the stability of the cetyl-PEG₂-enkephalin conjugate as compared to free met-enkephalin-lys. Figure 3 shows the stability of the cetyl-PEG₃-enkephalin as

Sub C13 C14 C15
compared to met-enkephalin-lysine. Figure 4 shows palmitate-PEG₃-enk (hydrolyzable) conjugate as compared to met-enkephalin-enk.

5.7.1 EXTRACTION AND DETECTION OF ENKEPHALIN CONJUGATES FROM THE BRAIN OF DOSED RATS

5 5.7.1.1 PROCEDURE

Sub C13 C14 C15
The following procedure was used to identify the presence of conjugate from the brain specimen of animals dosed with 5 mg/kg cetyl-PEG₂-enkephalin.

After 10 minutes of dosing, the brain of the animal was perfused with 1.5% trifluoroacetic acid in PBS solution, and the brain was removed and frozen at -70 °C.

10 The brain was homogenized with 1mL of 1.5% trifluoroacetic acid in PBS solution and the homogenate was extracted with acetonitrile/isopropanol solution. The extract was treated with saturated sodium chloride solution and frozen at -20 °C for 2 hours. The organic layer was isolated and centrifuged at 4000RPM. The supernatant was evaporated and the resulting residue was reconstituted in acetonitrile/isopropanol/water mixture. The reconstituted solution was analyzed by HPLC using a gradient of 10 to 100% isopropanol/water (0.1% trifluoroacetic acid) on a C-18 column. The presence and the concentration of cetyl-PEG₂-enkephalin conjugate in the extract were measured by comparing the retention time and the peak area of standard solution under the same analytical condition. The results are presented in FIGs 5A to 5D.

20 5.7.1.2 RESULTS

Sub C13 C14 C15
The results demonstrate that monoconjugates were isolated from brain tissue. FIG 5A shows a peak produced by cetyl enkephalin standard, while 5B shows a corresponding peak demonstrating that cetyl enkephalin was actually present in the brain extract. In contrast, neither the vehicle (FIG. 5C) nor the unconjugated enkephalin (FIG. 5D) showed a corresponding peak.

5.8 RAT PAW-HOT PLATE TEST

5.8.1 ANIMALS

Adult, male Sprague-Dawley rats weighing 150-175 g were obtained from Charles River Breeding Laboratories (Raleigh, NC) and used for all animal studies. Rats were housed in hanging wire-bottomed cages in a vivarium equipped with a 12:12 light:dark cycle and 5 humidity was maintained between 45-65% with a room temperature of $72 \pm 2^{\circ}\text{C}$. Rats were provided Purina Rodent Chow and tap water ad libitum.

5.8.2 METHODS

Met-enkephalin-lys and met-enkephalin-lys derivatives were assessed for analgesic activity by rat paw-hot plate assay. Rats were given an injection of naloxone at 0.5 mg/kg (s.c.) then administered a single administration of cetyl-enkephalin by the tail vein 10 minutes later at a dose of 5.0 mg/kg. The results as graphically displayed in FIG. 6 demonstrate that Naloxone, an μ -receptor antagonist prevents competitively inhibits binding of cetyl-PEG₂-enkephalin, thus demonstrating that at least part of the activity of cetyl-PEG₂-enkephalin is attributable to binding at the Opioid μ -receptor.

5 In a separate study, rats were administered cetyl-enkephalin (5.0 mg/kg, i.v.) or clonidine (0.125 mg/kg, i.v.).

10 The latency to rat paw withdrawal from the hot plate was measured by a Hot Plate Analgesia Meter (Harvard Apparatus Ltd., Kent, England). The temperature of the hot plate was set and calibrated at 52 °C and rats were removed from the heat stimulus by 20 36 seconds after placement. Latency trials were terminated when the animal was either licking a hind paw or initiating a jump from the plate. Baseline measurements were collected 1 hour prior to drug administration and at various times post-injection, dependent upon the study conducted. All hot plate testing was terminated by 1 hour after drug dosing.

25 5.8.3 RESULTS

20 The results are displayed in the following tables and in the Graph of FIG 6. The results demonstrate that while 20 mg/kg enkephalin alone has 0% analgesic effect as compared

*Sub
act
can*

to morphine as a baseline, the enkephalin conjugates of the present invention had strong analgesic effects and one conjugate, DHA-PEG-ENK had 130% of the analgesic effect of morphine. The graph of FIG. 7 shows that CETYL-PEG-ENK produces a response and duration comparable to that of clonidine, an α -adrenergic receptor agonist.

*Sub
act
can*

| Drug or Conjugate | Dose (mg/kg) | Number of Rats | Mean Analgesia as Compared with Morphine at 3 mg/Kg* | |
|---------------------|--------------|----------------|--|----------|
| | | | @ 5 min | @ 30 min |
| Morphine | 3 | 8 | 100% | 100% |
| Enkephalin | 20 | 7 | 0% | 0% |
| Cetyl-PEG-ENK | 5 | 8 | 84% | 75% |
| DHA-PEG-ENK | 20 | 8 | 130% | 67% |
| Cholesterol-PEG-ENK | 5 | 8 | 80% | 68% |
| Linolenic-PEG-ENK | 10 | 8 | 77% | 73% |

5

5.9 AGONIST-STIMULATED [^{35}S] GTP γ S BINDING IN BRAIN SECTIONS.

5.9.1 MATERIALS

Male Sprague-Dawley rats (200 g) were purchased from Zivic-Miller (Zelienople, PA). *10* [^{35}S]GTP γ S (1250 Ci/mmol) was purchased from New England Nuclear Corp. (Boston, MA). [D-Ala², N-Me-Phe⁴,Gly⁵-ol]-enkephalin (DAMGO), adenosine deaminase, and GDP were obtained from Sigma Chemical Co. (St. Louis, MO). Reflections® autoradiography film was purchased from New England Nuclear Corp. (Boston, MA). All other reagent grade chemicals were obtained from Sigma Chemical Co. or Fisher.

15 5.9.2 AGONIST-STIMULATED [^{35}S] GTP γ S BINDING IN BRAIN SECTIONS.

Agonist-stimulated [³⁵S]GTP γ S autoradiography was performed as described by Sim et al. *Proc. Nat'l. Acad. Sci. USA* 1992 Pg. 7242 – 7246. Animals were sacrificed by decapitation and brains were removed and frozen in isopentane at -30°C. Coronal and horizontal brain sections were cut on a cryostat maintained at -20°C. Sections were 5 incubated in assay buffer (50 mM Tris-HCl, 3 mM MgCl₂, 0.2 mM EGTA, 100 mM NaCl, pH 7.4) at 25°C for 10 min. Sections were then incubated in assay buffer containing 2 mM GDP, protease inhibitor cocktail (10 μ l/ml of a solution containing 0.2 mg/ml each of bestatin, leupeptin, pepstatin A and aprotinin), and adenosine deaminase (9.5 mU/ml) at 25°C for 15 min. Sections were then incubated in assay buffer with GDP, 0.04 nM 10 [³⁵S]GTP γ S and appropriate agonist at 25°C for 2 hours. The agonists were: 10 μ M DAMGO, 10 μ M cetyl-enkephalin and 10 μ M cetyl-TEG-enkephalin. Basal binding was assessed in the absence of agonist. Slides were rinsed twice for 2 min each in cold Tris buffer (50 mM Tris-HCl, pH 7.4) and once in deionized H₂O. Slides were dried overnight and exposed to film for 72 hours. Films were digitized with a Sony XC-77 video camera 15 and analyzed using the NIH IMAGE program for Macintosh computers.

Sub 2005

5.9.3 RESULTS

Results show that cetyl-TEG-enkephalin stimulates of [³⁵S]GTP γ S binding. The anatomical distribution of the binding is consistent with that of μ Opioid receptors. These 20 results demonstrate that cetyl-TEG-enkephalin does not simply bind the receptor but also activates the receptor, causing the receptor to bind to G-protein. This activation provides further corroborative evidence that cetyl-TEG-enkephalin directly stimulates analgesia.